대한암한의학회지 (Journal of Korean Traditional Oncology)

  • 제21권2호
  • /
  • Pages.1-35
  • /
  • 2016
  • /
  • 1975-244X(pISSN)
  • /
  • 2765-4850(eISSN)
대한암한의학회 (Korean Association of Traditional Oncology)
권호 표지
DOI QR코드

DOI QR Code

전립선암 치료의 한방 임상 진료 지침

Clinical Practice Guideline on Prostate Cancer in Korean Medicine

  • 송봉근 (원광대학교 한의과대학 내과학교실) ;
  • 이언정 (원광대학교 한의과대학 내과학교실) ;
  • 유화승 (대전대학교 둔산한방병원 동서암센터)
  • Song, Bong-Keun (Department of Internal Medicine, School of Korean Medicine, Wonkwang University) ;
  • Lee, Eun-Jung (Department of Internal Medicine, School of Korean Medicine, Wonkwang University) ;
  • Yoo, Hwa-Seung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejon University)
  • 투고 : 2016.11.18
  • 심사 : 2016.12.05
  • 발행 : 2016.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : The aim of this preliminary study is to suggest a clinical approach on prostate cancer through the analysis of existing clinical practice guidelines or clinical studies. Materials and Methods : The data related on the treatment of prostate cancer were collected using various search engines such as Pub Med, KIOM OASIS, CNKI. Then, data were analyzed to evaluate the validity of recommendation of treatment. Results : Prostate cancer has the highest prevalence around the world. Recently, the incidence of prostate cancer in Korea is rapidly increasing. Especially, it was reported that incidence rate rose up to 80% by age 80 years. In recent studies, applying combined traditional and conventional medicine were reported to improve the survival, quality of life, immune function, and suppress of tumor growth in prostate cancer. However there has not been an objective and systemic clinical guideline for prostate cancer in Korean Medicine. Accordingly, it has been difficult for doctors to apply optimized therapeutic treatment in clinics. This study will show a preliminary approach to establish clinical practice guideline for prostate cancer of Korean Medicine. Conclusion : Further objective and systemic clinical studies by Korean Medicine are needed to develop more advanced clinical practice guidelines of prostate cancer.

키워드

참고문헌

  1. World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.11.
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin 2013;63:11-30. https://doi.org/10.3322/caac.21166
  3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26. https://doi.org/10.3322/canjclin.53.1.5
  4. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92. https://doi.org/10.1016/j.eururo.2012.02.054
  5. Jung KW, Wong YJ, Kong HJ, Oh CM, Cho H et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in2002. Cancer Res Treat, 2015, 47(2):127-41. https://doi.org/10.4143/crt.2015.060
  6. 국가암정보센터. 통계로 알아보는 암. Available at http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.
  7. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett. Human prostate cancer risk factors.Cancer. 2004;101(10 Suppl):2371-490. https://doi.org/10.1002/cncr.20408
  8. 林洪生. 惡性腫瘤中医診療指南. pp 499-515, 北京,人民衛生出版社, 2014.
  9. The American Urological Asscociation Prostate Cancer Clinical Guidelines Panel. The management of clinically localized prostate cancer. Linthicum. MD, USA 1995 pp 1-88.
  10. Mottet N, Bellmunt J, Briers E, van den Bergh RC, van Casteren NJ, Cornford P et al. Guidelines on prostate cancer. European Association of Urology. P56-63, 2015.
  11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology; prostate cancer. Version 1. 2014. NCCN.org.
  12. 대한비뇨기종양학회. 전립선암 진료지침. pp 16,18,20-21, 서울, 펜타이드, 2009.
  13. 대한비뇨기종양학회. 전립선암 진료지침. 2015. Available at http://www.kuos.or.kr/05/05condition.asp.
  14. 홍상훈, 손호영. 간세포종 치료에 대한 한의 임상 가이드라인. 대한암한의학회지 2015; 20(1):55-79.
  15. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151(5);1283-90. https://doi.org/10.1016/S0022-5347(17)35233-3
  16. Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract. 1999;16(6):621-6. https://doi.org/10.1093/fampra/16.6.621
  17. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42(4):365-74. https://doi.org/10.1016/0090-4295(93)90359-I
  18. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only.Urology. 2007;70(6):1117-20. https://doi.org/10.1016/j.urology.2007.07.019
  19. Gosselaar C, Roobol MJ, Roemeling S, Schroder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol. 2008;54(3):581-8. https://doi.org/10.1016/j.eururo.2008.03.104
  20. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, Schroder FH. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79-85. https://doi.org/10.1016/j.eururo.2009.08.025
  21. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 1990;16(3):187-97. https://doi.org/10.1002/pros.2990160302
  22. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia.Eur Urol. 1996;30(2):138-44. https://doi.org/10.1159/000474163
  23. American Cancer Society. Cancer Facts & Figures 2015. Atlanta, Ga: American Cancer Society; 2015.
  24. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data.
  25. Dijkman GA, Debruyne FM. Epidemiology of prostate cancer. Eur Urol. 1996;30(3):281-95. https://doi.org/10.1159/000474185
  26. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42:3232-9.
  27. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus Serum Bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997;6:967-9.
  28. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993; 150:797-802. https://doi.org/10.1016/S0022-5347(17)35617-3
  29. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337-47. https://doi.org/10.1002/pros.2990170409
  30. Eeles RA, Collaborators TUFPSC-oGtCBUFPCS. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 1999;2:9-15. https://doi.org/10.1038/sj.pcan.4500279
  31. Glover FE Jr., Coffey DS, Douglas LL, et al. Familial study of prostate cancer in Jamaica. Urology. 1998;52:441-3. https://doi.org/10.1016/S0090-4295(98)00200-3
  32. Gronberg H, Wiklund F, Damber JE. Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations. Cancer. 1999;86:477-83. https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<477::AID-CNCR16>3.0.CO;2-K
  33. Hartman TJ, Albanes D, Rautalahti M, et al. Physical activity and prostate cancer in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study (Finland). Cancer Causes Control. 1998;9:11-8. https://doi.org/10.1023/A:1008889001519
  34. Heinonen OP, Albanes D, Virtamo J. Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and betacarotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998;90:440-6. https://doi.org/10.1093/jnci/90.6.440
  35. Mangels AR, Holden JM, Beecher GR, Forman MR, Lanza E. Carotenoid content of fruits and vegetables: an evaluation of analytic data. J Am Diet Assoc. 1993;93: 284-96. https://doi.org/10.1016/0002-8223(93)91553-3
  36. Clark LC, Combs GF Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957-63. https://doi.org/10.1001/jama.1996.03540240035027
  37. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett C. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control. 1998;9:3-9. https://doi.org/10.1023/A:1008822917449
  38. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol. 1990;132:895-901. https://doi.org/10.1093/oxfordjournals.aje.a115732
  39. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1992;117:807-11. https://doi.org/10.7326/0003-4819-117-10-807
  40. Talamini R, La Vecchia C, Decarli A, Negri E, Franceschi S. Nutrition, social factors and prostatic cancer in a Northern Italian population. Br J Cancer. 1986;53:817-21. https://doi.org/10.1038/bjc.1986.138
  41. Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer. 1997;73:634-8. https://doi.org/10.1002/(SICI)1097-0215(19971127)73:5<634::AID-IJC4>3.0.CO;2-Y
  42. Irani J, Lefebvre O, Murat F, Dahmani L, Dore B. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int. 2003;91:482-484. https://doi.org/10.1046/j.1464-410X.2003.04133.x
  43. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87:652-61. https://doi.org/10.1093/jnci/87.9.652
  44. Howell MA. Factor analysis of international cancer mortality data and per capita food consumption. Br J Cancer. 1974;29:328-36. https://doi.org/10.1038/bjc.1974.75
  45. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 1975;15: 617-31. https://doi.org/10.1002/ijc.2910150411
  46. Blair A, Fraumeni JF. Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst. 1978;61: 1379-84.
  47. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer. 1989;64:598-604. https://doi.org/10.1002/1097-0142(19890801)64:3<598::AID-CNCR2820640306>3.0.CO;2-6
  48. Le Marchand L, Kolonel LN, Wilkens LR, Myers BC, Hirohata T. Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology. 1994;5:276-82. https://doi.org/10.1097/00001648-199405000-00004
  49. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control. 2001;12:557-67. https://doi.org/10.1023/A:1011256201044
  50. West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control. 1991;2:85-94. https://doi.org/10.1007/BF00053126
  51. Ghadirian P, Lacroix A, Maisonneuve P, et al. Nutritional factors and prostate cancer: a case-control study of French Canadians in Montreal, Canada. Cancer Causes Control. 1996;7:428-36. https://doi.org/10.1007/BF00052669
  52. Lee MM, Wang RT, Hsing AW, Gu FL, Wang T, Spitz M. Case-control study of diet and prostate cancer in China. Cancer Causes Control. 1998;9:545-52. https://doi.org/10.1023/A:1008840105531
  53. Tzonou A, Signorello LB, Lagiou P, Wuu J, Trichopoulos D, Trichopoulou A. Diet and cancer of the prostate: a case-control study in Greece. Int J Cancer. 1999 Mar 1;80(5):704-8. https://doi.org/10.1002/(SICI)1097-0215(19990301)80:5<704::AID-IJC13>3.0.CO;2-Z
  54. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxford). 1997;46: 333-42.
  55. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? [Hypothesis.] Anticancer Res. 1990;10(5A):1307-11.
  56. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993;2:467-72.
  57. Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control. 1998;9:567-82. https://doi.org/10.1023/A:1008835903714
  58. Peehl DM. Vitamin D and prostate cancer risk. Eur Urol. 1999;35(5-6):392-4. https://doi.org/10.1159/000019914
  59. Polek TC, Weigel NL. Vitamin D and prostate cancer. J Androl. 2002;23:9-17. https://doi.org/10.1002/j.1939-4640.2002.tb02596.x
  60. Sigounas G, Anagnostou A, Steiner M. dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer. 1997;28:30.35. https://doi.org/10.1080/01635589709514549
  61. Andersson SO, Wolk A, Bergstrom R, et al. Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer. 1996;68:716-22. https://doi.org/10.1002/(SICI)1097-0215(19961211)68:6<716::AID-IJC4>3.0.CO;2-6
  62. Ross RK, Shimizu H, Paganini-Hill A, Honda G, Henderson BE. Case-control studies of prostate cancer in blacks and whites in southern California. J Natl Cancer Inst. 1987;78:869-74.
  63. Hsing AW, McLaughlin JK, Schuman LM, et al. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res. 1990;50: 6836-40.
  64. Whittemore AS, Wu ML, Paffenbarger RS Jr., et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 1988;128: 1228-40. https://doi.org/10.1093/oxfordjournals.aje.a115077
  65. Checkoway H, DiFerdinando G, Hulka BS, Mickey DD. Medical, life-style, and occupational risk factors for prostate cancer. Prostate. 1987;10:79-88. https://doi.org/10.1002/pros.2990100111
  66. Adami HO, McLaughlin JK, Hsing AW, et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control. 1992;3:419-25. https://doi.org/10.1007/BF00051354
  67. Talamini R, Franceschi S, La Vecchia C, Serraino D, Barra S, Negri E. Diet and prostatic cancer: a case-control study in northern Italy. Nutr Cancer. 1992;18:277 -86. https://doi.org/10.1080/01635589209514228
  68. Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate. 1985;6:423-36. https://doi.org/10.1002/pros.2990060411
  69. La Vecchia C, Negri E, D’Avanzo B, Franceschi S, Boyle P. Dairy products and the risk of prostatic cancer. Oncology. 1991;48:406-10. https://doi.org/10.1159/000226970
  70. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control. 1998;9:559 -66. https://doi.org/10.1023/A:1008823601897
  71. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst. 1998;90:1637-47. https://doi.org/10.1093/jnci/90.21.1637
  72. Grant WB. An ecologic study of dietary links to prostate cancer. Altern Med Rev. 1999;4:162-9.
  73. Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev. 2003;12:597-603.
  74. Watson CS, Pappas TC, Gametchu B. The other estrogen receptor in the plasma membrane: implications for the actions of environmental estrogens. Environ Health Perspect. 1995;103(Suppl 7):41-50. https://doi.org/10.1289/ehp.95103s741
  75. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996;93:5925-30. https://doi.org/10.1073/pnas.93.12.5925
  76. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118:793-803. https://doi.org/10.7326/0003-4819-118-10-199305150-00007
  77. Sorahan T, Waterhouse JA, McKiernan MJ, Aston RH. Cancer incidence and cancer mortality in a cohort of semiconductor workers. Br J Ind Med. 1985;42:546-50.
  78. Thun MJ, Schnorr TM, Smith AB, Halperin WE, Lemen RA. Mortality among a cohort of U.S. cadmium production workers-an update. J Natl Cancer Inst. 1985;74:325-33.
  79. Keller-Byrne JE, Khuder SA, Schaub EA. Meta-analyses of prostate cancer and farming. Am J Ind Ind Med. 1997;31:580-Ind Med. 1997;31:580-6. https://doi.org/10.1002/(SICI)1097-0274(199705)31:5<580::AID-AJIM13>3.0.CO;2-V
  80. Williams RR, Stegens NL, Goldsmith JR. Associations of cancer site and type with occupation and industry from the Third National Cancer Survey Interview. J Natl Cancer Inst. 1977;59:1147-85. https://doi.org/10.1093/jnci/59.4.1147
  81. McMichael AJ, Spirtas R, Kupper LL. An epidemiologic study of mortality within a cohort of rubber workers, 1964-72. J Occup Med. 1974;16:458-64.
  82. Monson RR, Nakano KK. Mortality among rubber workers. I. White male union employees in Akron, Ohio. Am J Epidemiol. 1976;103:284-96. https://doi.org/10.1093/oxfordjournals.aje.a112226
  83. Delzell E, Louik C, Lewis J, Monson RR. Mortality and cancer morbidity among workers in the rubber tire industry. Am J Ind Med. 1981;2:209-16. https://doi.org/10.1002/ajim.4700020304
  84. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989;49:1857-60.
  85. Engeland A, Andersen A, Haldorsen T, Tretli S. Smoking habits and risk of cancers other than lung cancer: 28 years’ follow-up of 26,000 Norwegian men and women. Cancer Causes Control. 1996;7:497-506. https://doi.org/10.1007/BF00051881
  86. Lotufo PA, Lee IM, Ajani UA, Hennekens CH, Manson JE. Cigarette smoking and risk of prostate cancer in the Physicians’ Health Study (United States). Int J Cancer. 2000; 87:141-4. https://doi.org/10.1002/1097-0215(20000701)87:1<141::AID-IJC21>3.0.CO;2-A
  87. Hiatt RA, Armstrong MA, Klatsky AL, Sidney S. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control. 1994;5:66-72. https://doi.org/10.1007/BF01830728
  88. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65_ Rural Health Study (United States). Cancer Causes Control. 1997;8:229-38. https://doi.org/10.1023/A:1018428531619
  89. Karlsson CT, Malmer B, Wiklund F, Gronberg H. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer? J Urol. 2006;176:538-43. https://doi.org/10.1016/j.juro.2006.03.036
  90. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:437-49. https://doi.org/10.1158/1055-9965.EPI-13-1165
  91. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. A prospective cohort study of vasectomy and prostate cancer in US men. JAMA. 1993;269:873-82. https://doi.org/10.1001/jama.1993.03500070053028
  92. Sidney S. Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy. J Urol. 1987;138:795-7. https://doi.org/10.1016/S0022-5347(17)43377-5
  93. Sidney S, Quesenberry CP Jr., Sadler MC, Guess HA, Lydick EG, Cattolica EV. Vasectomy and the risk of prostate cancer in a cohort of multiphasic health-checkup examinees: second report. Cancer Causes Control. 1991;2:113-6. https://doi.org/10.1007/BF00053130
  94. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7thed NewYork, NY: Springer; 2010:457-64.
  95. Humhrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology 2004;17,292-396 https://doi.org/10.1038/modpathol.3800054
  96. American Urologival Association. Guidelines for the management of clinically localized postate cancer;2007. 2007 p.10 Linthicum. MD, USA.
  97. Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol 2014;24(3):288-92. https://doi.org/10.1097/MOU.0000000000000039
  98. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28(1):126-31. https://doi.org/10.1200/JCO.2009.24.2180
  99. Adolfsson J. Watchful waiting and active surveillance: the current position. BJU Int 2008;102(1):10-4. https://doi.org/10.1111/j.1464-410X.2008.07585.x
  100. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330(4):242-8. https://doi.org/10.1056/NEJM199401273300403
  101. Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000;56(3):442-7. https://doi.org/10.1016/S0090-4295(00)00696-8
  102. Johansson JE, Adami HO, Andersson SO, et al. Natural history of localized prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989;1(8642):799-803.
  103. Bill-Axelson A, Holmberg L, Ruutu M, et al. for the Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84. https://doi.org/10.1056/NEJMoa043739
  104. Adolfsson J, Tribukait B, Levitt S. The 20-yr outcome in patients with well-or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol 2007;52(4):1028-35. https://doi.org/10.1016/j.eururo.2007.04.002
  105. Jonsson E, Sigbjarnarson HP, Tomasson J, et al. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol 2006;40(4):265-71. https://doi.org/10.1080/00365590600750110
  106. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302(11):1202-9. https://doi.org/10.1001/jama.2009.1348
  107. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370(10):932-42. https://doi.org/10.1056/NEJMoa1311593
  108. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostatecancer. N Engl J Med 2012;367(3):203-13. https://doi.org/10.1056/NEJMoa1113162
  109. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285-90. https://doi.org/10.1016/j.ijrobp.2004.08.047
  110. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11(11):1066-73. https://doi.org/10.1016/S1470-2045(10)70223-0
  111. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long term results of RTOG 8610. J Clin Oncol 2008; 26(4):585-91. https://doi.org/10.1200/JCO.2007.13.9881
  112. D’Amico A, Renshaw AA, Loffredo M, et al. Androgen suppression and radiation vs radiation alone for prostate cancer; a randomized controlled trial. JAMA 2008;299(3):289-95. https://doi.org/10.1001/jama.299.3.289
  113. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12(5):451-9. https://doi.org/10.1016/S1470-2045(11)70063-8
  114. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77. https://doi.org/10.7326/0003-4819-132-7-200004040-00009
  115. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102(11):1531-8. https://doi.org/10.1111/j.1464-410X.2008.08183.x
  116. McLeod DG, Zinner N, Tomera K, et al. A phase 3, multicentre, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-61. https://doi.org/10.1016/S0090-4295(01)01342-5
  117. Donnelly BJ, Saliken JC, Brasher PM, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116(2):323-30. https://doi.org/10.1002/cncr.24779
  118. Madersbacher S, Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol 2003;17(8):667-72. https://doi.org/10.1089/089277903322518680
  119. 龐然; 高筱松; 盧建新; 劉兵; 宋竪旗; 薄海; 張亞强. 前列消癥湯治療激素難治性前列腺癌臨床觀察. 北京中医藥, 2010;29(12):918-9.
  120. 龐然, 盧建新, 高筱松, 劉兵, 宋竪旗. 前列消癥湯治療激素難治性前列腺癌的臨床硏究. 中國中西医結合外科雜志, 2013;4:374-7.
  121. 楊莹, 肖永剛, 吳楠. 柴胡桂枝湯聯合125I介入治療對前列腺癌患者生活質量和總生存率的影響. 現代中西医結合雜志, 2015;21:2324-26.
  122. 吳燕敏, 馬國花, 魏睦新. 知柏地黃湯加味治療早期前列腺癌38例. 時珍國医國藥, 2009;20(4):951-2.
  123. 余紹龍, 陳智鋒, 林峰, 黄小琴, 溫志鹏. 六味地黄湯聯合内分泌治療晚期 前列腺癌的臨床觀察. 中國当代医藥, 2010;17(24):93-3.
  124. 周紅, 何秀云, 鄒清芳.六味地黃湯加味聯合比卡鲁胺治療晚期前列腺癌療效觀察. 四川中医, J 2013;(6):95-6.
  125. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells.Clin Cancer Res. 2002;8(8):2666-74.
  126. Liu Q. Triptolide and its expanding multiple pharmacological function. Int Immunopharmacol. 2011;11(3):377-83. https://doi.org/10.1016/j.intimp.2011.01.012
  127. Capodice JL, Gorroochurn P, Cammack AS etal. Zyflamend in men with high-grade prostatic intraepithelial neoplasia:results of a phase I clinical trial. J Soc Integr Oncol 2009;7:43-51.
  128. Yan J, Xie B ,Capodice JL et al. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Prostate 2012;72:244-52. doi: 10.1002/pros.21426.
  129. Kunnumakkara AB, Sung B, Ravindran J et al. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer 2011; Sep 20 [E-pub ahead of print]. doi: 10.1002/ijc.26442.
  130. Cao H, Mu Y, Li X, Wang Y, Chen S, Liu JP. A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer. PLoS One. 2016;4;11(8):e0160253. https://doi.org/10.1371/journal.pone.0160253
  131. 石芳毓, 李金龍, 張明霞, 馬继春, 田金徽. 鴉胆子油乳聯合内分泌治療中晚期前列腺癌有效性和安全性的Meta分析. 中國藥物評价, 2014;5:289-94.
  132. 張育軍, 雒向宁. 鴉胆子油乳聯合内分泌治療中晚期前列腺癌. 現代中西医結合雜志 ,2010;19(12):1464-65.
  133. 陳曉農, 王榮江. 参附注射液对晚期前列腺癌患者的PSA水平及生存質量的影響, 中華中医藥學刊, 2014;6:1459-61.
  134. 胡克邦.复方苦参注射液配合内分泌療法治療中晚期前列腺癌骨轉移的療效觀察. 潦宁中医雜志, 2014;10:2174-5.
  135. 黄和濤, 溫忠霖. 蜂針配合中藥治療前列腺癌骨轉移一則. 中國民間療法, 2014;4:59-9.
  136. 呂立國, 陳志强, 吳巧玲, 白遵光, 王昭輝. 蜂針療法治療前列腺癌的臨床應用. 新中医, 2014;46(12):254-5.
  137. 양창열, 송호섭. Bee venom의 세포자멸사를 통한 전립선 암세포의 성장 및 LNCaP의 이종이식에 미치는 영향. 대한약침학회지 13(1);2010:15-35.
  138. 오현준, 송호섭. Bee Venom이 NF-${\kappa}B$의 불활성화에 의한 세포자멸사를 통해 PC-3 세포의 증식에 미치는 영향. 대한침구학회지27(3);2010:1-13.
  139. 윤종일, 송호섭. Melittin의 전립선암세포 증식에 대한 억제 효과. 대한침구학회지 24(2);2007:51-61.
  140. Beer TM, Benavides M, Emmons SL, Hayes M, Liu G, Garzotto M, Donovan D, Katovic N, Reeder C, Eilers K. Acupuncture for hot flashes in patients with prostate cancer. Urology. 2010;76(5):1182-8. https://doi.org/10.1016/j.urology.2010.03.033
  141. Filshie J, Bolton T, Browne D, Ashley S. Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients--audit and treatment algorithm. Acupunct Med. 2005 ;23(4):171-80. https://doi.org/10.1136/aim.23.4.171
  142. 楊美倫. 溫針八髎穴佐治前列腺癌术后尿失禁的臨床觀察及護理. 山東医學高等專科學校學報, 2012;34(3):203-204.
  143. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008;12:1-23.
  144. Nam RK, Fleshner N, Rakovitch E et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiologic analysis. J Urol 1999;161:1521-24. https://doi.org/10.1016/S0022-5347(05)68943-4
  145. McDermott CL, Blough DK, Fedorenko CR et al. Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer 2012;20:65-73. https://doi.org/10.1007/s00520-010-1055-y
  146. Jacobson JS, Chetty AP. Complementary and alternative medicine in prostate cancer. Curr Oncol Rep 2001;3:448-52. https://doi.org/10.1007/s11912-001-0032-5
  147. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression.J Clin Oncol 2005;23:8152-60. https://doi.org/10.1200/JCO.2005.03.1492
  148. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The Selenium and Vitamin E Cancer Prevention Trial (SELECT).JAMA 2009;301:39-51.
  149. Klein EA, Thompson IM Jr, Tangen CM et al. Vitamin E and the risk of prostate cancer:the Selenium andVitamin E Cancer Prevention Trial (SELECT).JAMA 2011;306:1549-56. https://doi.org/10.1001/jama.2011.1437
  150. Longtin R. The pomegranate: nature's power fruit? J Natl Cancer Inst 2003;95:346-8. https://doi.org/10.1093/jnci/95.5.346
  151. Seeram NP, Zhang Y, McKeever R et al. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 2008;11:390-4. https://doi.org/10.1089/jmf.2007.650
  152. Malik A, Afaq F, Sarfaraz S et al. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A 2005;102: 14813-8. https://doi.org/10.1073/pnas.0505870102
  153. Pantuck AJ, Leppert JT, Zomorodian N et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12:4018-26. https://doi.org/10.1158/1078-0432.CCR-05-2290
  154. Bettuzzi S, Brausi M, Rizzi F et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66: 1234-40. https://doi.org/10.1158/0008-5472.CAN-05-1145
  155. Henning SM, Wang P, Heber D. Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol Nutr Food Res 2011;55: 905-20. https://doi.org/10.1002/mnfr.201000648
  156. Shi WF, Leong M, Cho E et al. Repressive effects of resveratrol on androgen receptor transcriptional activity.PLoS One 2009;4:e7398. https://doi.org/10.1371/journal.pone.0007398
  157. Harada N, Murata Y, Yamaji R et al. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2007;53:556-60. https://doi.org/10.3177/jnsv.53.556
  158. Stattin P, Bylund A, Rinaldi S et al. Plasma insulin-like growth factor-I insulin-like growth factor binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7. https://doi.org/10.1093/jnci/92.23.1910
  159. Zi X, Zhang J, Agarwal R et al. Silibinin upregulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000;60: 5617-20.